{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:54:42Z","timestamp":1778140482759,"version":"3.51.4"},"reference-count":84,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI for older patients. A multidisciplinary task force from the French Society of Geriatric Oncology (SoFOG) and the French Society of Pulmonology\/Oncology Group (SPLF\/GOLF) conducted a systematic review from May 2010 to May 2021. Protocol registered in Prospero under number CRD42021224103. Three key questions were selected for older patients with NSCLC: (1) to whom TKI can be proposed, (2) for whom monotherapy should be favored, and (3) to whom a combination of TKI can be proposed. Among the 534 references isolated, 52 were included for the guidelines. The expert panel analysis concluded: (1) osimertinib 80 mg\/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. Malnutrition, functional decline, and the number of comorbidities should be assessed primarily before TKI initiation.<\/jats:p>","DOI":"10.3390\/cancers14030769","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T22:16:18Z","timestamp":1643753778000},"page":"769","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)\/French-Language Oncology Group (GOLF)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-9503","authenticated-orcid":false,"given":"Laurent","family":"Greillier","sequence":"first","affiliation":[{"name":"Multidisciplinary Oncology and Therapeutic Innovations Department, AP-HM Marseille France, Aix-Marseille University, CNRS INSERM CRCM, F-13009 Marseille, France"},{"name":"French-Language Society of Pulmonology (SPLF), F-75006 Paris, France"},{"name":"French-Language Oncology Group (GOLF), F-75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Gauvrit","sequence":"additional","affiliation":[{"name":"Inserm CIC1401 Institut Bergoni\u00e9 Clinical Research Plateform for Older Patients with Cancer (PACAN), F-33076 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-9927","authenticated-orcid":false,"given":"Elena","family":"Paillaud","sequence":"additional","affiliation":[{"name":"Department of Geriatrics Geriatric Oncology Clinic HEGP Paris Cancer Institute CARPEM, AP-HP, F-75015 Paris, France"},{"name":"Faculty of Health, Universit\u00e9 Paris, F-75006 Paris, France"},{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"French-Language Society of Pulmonology (SPLF), F-75006 Paris, France"},{"name":"French-Language Oncology Group (GOLF), F-75006 Paris, France"},{"name":"Thorax Institute Curie-Montsouris, F-75014 Paris, France"},{"name":"UVSQ Paris, F-78000 Saclay, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coline","family":"Mont\u00e9gut","sequence":"additional","affiliation":[{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"Internal Medicine Geriatrics and Therapeutic Unit AP-HM, F-13009 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-4250","authenticated-orcid":false,"given":"Rabia","family":"Boulahssass","sequence":"additional","affiliation":[{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"Coordination Unit of Geriatric Oncology Rehabilitation and Autonomy Department University Hospital of Nice, F-06000 Nice, France"},{"name":"Nice Sophia Antipolis, University Onco-Age, F-06100 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[{"name":"French-Language Society of Pulmonology (SPLF), F-75006 Paris, France"},{"name":"French-Language Oncology Group (GOLF), F-75006 Paris, France"},{"name":"Oncology Thoracic Unit Pulmonology Department AP-HP H\u00f4pital Cochin, F-75014 Paris, France"},{"name":"Paris University Centre de Recherche des Cordeliers, Sorbonne University INSERM Team Inflammation Complement and Cancer, F-75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-9857","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Pamoukdjian","sequence":"additional","affiliation":[{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"Geriatric Department APHP, Avicenne Hospital, F-93000 Bobigny, France"},{"name":"I SERM UMR_S942 Cardiovascular Markers in Stressed Conditions MASCOT, Sorbonne Paris Nord University, F-93000 Bobigny, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Corre","sequence":"additional","affiliation":[{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"Pulmonology Department Cornouaille Hospital, F-29000 Quimper, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Cabart","sequence":"additional","affiliation":[{"name":"Oncology Department Institut Bergoni\u00e9, F-33076 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Caillet","sequence":"additional","affiliation":[{"name":"Department of Geriatrics Geriatric Oncology Clinic HEGP Paris Cancer Institute CARPEM, AP-HP, F-75015 Paris, France"},{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"INSERM U955 IRMB Universit\u00e9 Paris-Est, F-94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaniss","family":"Belaroussi","sequence":"additional","affiliation":[{"name":"Inserm CIC1401 Institut Bergoni\u00e9 Clinical Research Plateform for Older Patients with Cancer (PACAN), F-33076 Bordeaux, France"},{"name":"Department of Thoracic Surgery Haut-Leveque Hospital Bordeaux University, University of Bordeaux, F-33000 Bordeaux, France"},{"name":"INSERM Bordeaux Population Health Research Center EPICeNE Team UMR 1219, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Frasca","sequence":"additional","affiliation":[{"name":"Inserm CIC1401 Institut Bergoni\u00e9 Clinical Research Plateform for Older Patients with Cancer (PACAN), F-33076 Bordeaux, France"},{"name":"Palliative Medicine Department CHU, F-33000 Bordeaux, France"},{"name":"Bordeaux Population Health Centre Recherche U1219, Equipe Cancer et Environnement EPICeNE, Bordeaux University, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[{"name":"Inserm CIC1401 Institut Bergoni\u00e9 Clinical Research Plateform for Older Patients with Cancer (PACAN), F-33076 Bordeaux, France"},{"name":"Clinical Pharmacology Department CHU Bordeaux, F-33000 Bordeaux, France"},{"name":"Univ Bordeaux INSERM BPH U1219 Team Pharmaco-Epidemiology, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-3765","authenticated-orcid":false,"given":"Pascal","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Thoracic Unit Pulmonology Department AP-HP H\u00f4pital Cochin, F-75014 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Mebarki","sequence":"additional","affiliation":[{"name":"Department of Geriatrics Geriatric Oncology Clinic HEGP Paris Cancer Institute CARPEM, AP-HP, F-75015 Paris, France"},{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mathoulin-Pelissier","sequence":"additional","affiliation":[{"name":"Inserm CIC1401 Institut Bergoni\u00e9 Clinical Research Plateform for Older Patients with Cancer (PACAN), F-33076 Bordeaux, France"},{"name":"Bordeaux Population Health Centre Recherche U1219, Equipe Cancer et Environnement EPICeNE, Bordeaux University, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-2201","authenticated-orcid":false,"given":"Anne-Laure","family":"Couderc","sequence":"additional","affiliation":[{"name":"French Society of Geriatric Oncology (SoFOG), F-63122 Ceyrat, France"},{"name":"Internal Medicine Geriatrics and Therapeutic Unit AP-HM, F-13009 Marseille, France"},{"name":"CNRS EFS ADES Aix-Marseille University, F-13015 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","article-title":"Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database","volume":"25","author":"Owonikoko","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_2","unstructured":"(2021, December 18). SEER Cancer Statistics Review, 1975\u20132010\u2014Previous Version\u2014SEER Cancer Statistics Review, Available online: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2010\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.13876","article-title":"Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the food and drug administration database","volume":"85","author":"Ruiter","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cllc.2011.11.010","article-title":"Delay between the initial symptoms, the diagnosis and the onset of specific treatment in elderly patients with lung cancer","volume":"13","author":"Labrune","year":"2012","journal-title":"Clin. Lung. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2016.05.007","article-title":"Relevance of a geriatric assessment for elderly patients with lung cancer-a systematic review","volume":"17","author":"Schulkes","year":"2016","journal-title":"Clin. Lung. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2017.12.013","article-title":"Patterns of treatment and survival among older patients with stage III non-small cell lung cancer","volume":"116","author":"Driessen","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_9","first-page":"61","article-title":"Frailty: A common pathway in aging and cancer","volume":"38","author":"Balducci","year":"2013","journal-title":"Interdiscip. Top. Gerontol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: The international society of geriatric oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.2147\/OTT.S140472","article-title":"Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer","volume":"10","author":"Tufman","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Enewold, L., and Thomas, A. (2016). Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156728"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fumagalli, C., Catania, C., Ranghiero, A., Bosi, C., Viale, G., de Marinis, F., Barberis, M., and Guerini-Rocco, E. (2019). Molecular profile of advanced non-small cell lung cancers in octogenarians: The door to precision medicine in elderly patients. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010112"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced alk-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","article-title":"Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET Exon 14 mutations: A retrospective analysis","volume":"133","author":"Awad","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2016.34.15_suppl.108","article-title":"Efficacy and safety of crizotinib in patients (Pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","unstructured":"Couraud, S., Westeel, V., Ranchon, F., Toffart, A.-C., and Souquet, P.J. (2021). Comit\u00e9 de R\u00e9daction des R\u00e9f\u00e9rentiels Auvergne Rh\u00f4ne-Alpes en; Oncologie Thoracique; Comit\u00e9 de R\u00e9daction de L\u2019\u00e9dition 2021 R\u00e9f\u00e9rentiel sur le Cancer Bronchique non \u00e0 Petites-Cellules: Actualisation 2021, ARISTOT."},{"key":"ref_23","unstructured":"(2021, August 12). La Valeur de l\u2019outil \u00ab Risque de Biais \u00bb de la Cochrane Collaboration Dans les Synth\u00e8ses M\u00e9thodiques. Available online: http:\/\/www.minerva-ebm.be\/FR\/Article\/2109."},{"key":"ref_24","unstructured":"(2021, August 12). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Available online: https:\/\/journals.plos.org\/plosmedicine\/article?id=10.1371\/journal.pmed.1000097."},{"key":"ref_25","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2013). Etat des Lieux-Niveau de Preuve et Gradation des Recommandations de Bonne Pratique, Haute Autorit\u00e9 de Sant\u00e9."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-018-1098-3","article-title":"A Phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations","volume":"35","author":"Tanaka","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2018.10.014","article-title":"A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations","volume":"126","author":"Imai","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Minegishi, Y., Yamaguchi, O., Sugawara, S., Kuyama, S., Watanabe, S., Usui, K., Mori, M., Hataji, O., Nukiwa, T., and Morita, S. (2021). A phase II study of first-line afatinib for patients aged \u226575 years with EGFR mutation-positive advanced non-small cell lung cancer: North east japan study group trial NEJ027. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07861-1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-012-0450-2","article-title":"Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: Retrospective analysis in a nagano lung cancer research group study","volume":"30","author":"Tateishi","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fujita, S., Katakami, N., Masago, K., Yoshioka, H., Tomii, K., Kaneda, T., Hirabayashi, M., Kunimasa, K., Morizane, T., and Mio, T. (2012). Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: A phase II trial. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-185"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1517\/14656566.2015.1002396","article-title":"First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies","volume":"16","author":"Morikawa","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00280-014-2548-z","article-title":"First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan lung study group 0901","volume":"74","author":"Takahashi","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-015-2841-5","article-title":"First-line gefitinib treatment in elderly patients (Aged \u226575 Years) with non-small cell lung cancer harboring EGFR mutations","volume":"76","author":"Kuwako","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cllc.2011.02.004","article-title":"Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: Results of a nagano lung cancer research group study","volume":"12","author":"Asami","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.18632\/oncotarget.23836","article-title":"Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: A multicentric real-world study assessing tolerance and efficacy (OCTOMUT Study)","volume":"9","author":"Corre","year":"2018","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.21873\/anticanres.12847","article-title":"Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment","volume":"38","author":"Furuta","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nakao, A., Hiranuma, O., Uchino, J., Sakaguchi, C., Araya, T., Hiraoka, N., Ishizuka, T., Takeda, T., Kawasaki, M., and Goto, Y. (2020). Final results from a phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790m-positive non-small cell lung cancer that progressed during previous treatment. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061762"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11523-019-00646-4","article-title":"Real-life efficacy of osimertinib in pretreated octogenarian patients with T790M-mutated advanced non-small cell lung cancer","volume":"14","author":"Auliac","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.21037\/jtd.2019.06.03","article-title":"Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"11","author":"Kato","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e201250","DOI":"10.1001\/jamaoncol.2020.1250","article-title":"Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter phase 2 trial","volume":"6","author":"Miyamoto","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2784-x","article-title":"Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations","volume":"76","author":"Inoue","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.cllc.2018.03.009","article-title":"Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: Subgroup analyses of the LUX-lung 3, LUX-lung 6, and LUX-lung 7 lrials","volume":"19","author":"Wu","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR Mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreatedEGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br. J. Cancer."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-lung 7 trial","volume":"28","author":"Tan","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000499086","article-title":"Efficacy and safety of ALK tyrosine kinase inhibitors in elderly patients with advanced ALK-positive non-small cell lung cancer: Findings from the real-life cohort","volume":"42","author":"Bedas","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.21873\/anticanres.11062","article-title":"Appetite loss as an adverse effect during treatment with EGFR-Tkis in elderly patients with non-small cell lung cancer","volume":"36","author":"Inomata","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/JTO.0b013e3181cee2d4","article-title":"Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients","volume":"5","author":"Wu","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"593\u2013e170","DOI":"10.1634\/theoncologist.2019-0003","article-title":"Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: A phase II trial","volume":"24","author":"Nakao","year":"2019","journal-title":"Oncologist"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-015-1214-9","article-title":"A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer cancer","volume":"8","author":"Minemura","year":"2015","journal-title":"BMC Res. Notes"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-010-0163-4","article-title":"Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: A phase II trial","volume":"5","author":"Rossi","year":"2010","journal-title":"Target. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2014.09.015","article-title":"Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of japanese patients with non-small-cell lung cancer","volume":"86","author":"Yoshioka","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Brueckl, W.M., Achenbach, H.J., Ficker, J.H., and Schuette, W. (2018). Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice\u2014Results from the ElderTac study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4208-x"},{"key":"ref_65","first-page":"2881","article-title":"Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)","volume":"36","author":"Yamada","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10637-020-00988-1","article-title":"Erlotinib and bevacizumab in elderly patients \u226575 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations","volume":"39","author":"Aoshima","year":"2021","journal-title":"Invest. New Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/jjco\/hyr087","article-title":"Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West japan thoracic oncology group study 0402","volume":"41","author":"Kobayashi","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2014.01.024","article-title":"Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin\/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer","volume":"84","author":"Heigener","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JTO.0b013e31823a39e8","article-title":"Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older","volume":"7","author":"Chen","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/annonc\/mdq630","article-title":"Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study","volume":"22","author":"Gridelli","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00048213","article-title":"Second-line therapy in elderly patients with advanced nonsmall cell lung cancer","volume":"43","author":"Quoix","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3892\/or.2012.1824","article-title":"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer","volume":"28","author":"Merimsky","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3892\/mco.2013.154","article-title":"Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the ibaraki thoracic integrative (POSITIVE) research group","volume":"1","author":"Kurishima","year":"2013","journal-title":"Mol. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00408-013-9498-9","article-title":"Treatment outcomes in elderly with advanced-stage non-small cell lung cancer","volume":"191","author":"Tam","year":"2013","journal-title":"Lung"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/JTO.0b013e3182835577","article-title":"A retrospective analysis of veristrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB\/IV non\u2013small-cell lung cancer","volume":"8","author":"Stinchcombe","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/JTO.0b013e3182210430","article-title":"A randomized phase ii trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age \u2265 70 years) with stage IIIB\/IV non-small cell lung cancer","volume":"6","author":"Stinchcombe","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.28261","article-title":"Molecular-targeted agents combination therapy for cancer: Developments and potentials","volume":"134","author":"Li","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Soubeyran, P., Bellera, C., Goyard, J., Heitz, D., Cur\u00e9, H., Rousselot, H., Albrand, G., Servent, V., Jean, O.S., and van Praagh, I. (2014). Screening for vulnerability in older cancer patients: The ONCODAGE prospective multicenter cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115060"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000062967","article-title":"The Mini Assessment (MNA) for grading the nutritional state of elderly patients: Presentation of the MNA, history and validation","volume":"1","author":"Guigoz","year":"1999","journal-title":"Nestle Nutr. Workshop Ser. Clin. Perform. Programme"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"J. Am. Med. Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","article-title":"Rating chronic medical illness burden in geropsychiatric practice and research: Application of the cumulative illness rating scale","volume":"41","author":"Miller","year":"1992","journal-title":"Psychiatry Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/769\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:49Z","timestamp":1760134369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030769"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030769","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}